Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2001 August;53(4) > Minerva Pediatrica 2001 August;53(4):265-70





A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532




Minerva Pediatrica 2001 August;53(4):265-70

language: English

Oxatomide in the treatment of atopic dermatitis in breast-fed and very young infants

Boccazzi A., Pugni L., Cesuti R., Rapuzzi S.


Background. This study was designed to assess the efficacy and safety of oxatomide oral suspension, in breast-fed and young babies with atopic dermatitis.
Methods. Thirty-one children (11 females, 20 males) aged between 4 and 35 months (mean± SD 15.4±7.6 months) were treated with oxatomide (2.5 mg/mL) at a dose of 1 mg/kg/day) split into two doses, every 12 hrs; treatment lasted 30 days. Efficacy was evaluated on the basis of the following signs and symptoms: itching (severity, extension and duration), blisters (number, extension), erythema (severity, extension), papules (number, extension), lesions from scratching (yes/no), dry skin (yes/no).
Results. Skin signs improved significantly with oxatomide. Itching was reduced 58.2% from baseline, and erythema 57.6% (both p<0.001). Vesicles, papules, lesions due to scratching and dry skin also improved significantly. Oxatomide had to be stopped only in one child in whom the dermatitis became worse.
Conclusions. These results show the efficacy and safety of oxatomide in breast-fed or very young babies with atopic dermatitis. The oral suspension was particularly easy to use in children less than two years old, on account of the simple dosage schedule.

top of page

Publication History

Cite this article as

Corresponding author e-mail